Cardio Diagnostics (CDIO) Short-Term Debt to Capital

Cardio Diagnostics (CDIO) focuses on developing AI systems for the epigenetic study of cardiac pathologies, implementing a subscription model for medical centers. This price chart featuring the 0.03 metric clearly illustrates the asset's dynamics amid fierce competition with tech giants and startups. Stability is driven by the development of genetic blood tests and the expansion of partnerships with insurance organizations and employers in the US.

This ratio determines the company's dependence on short-term liabilities relative to its equity, while the historical trend of short-term debt to equity allows for an assessment of liquidity risk and working capital management efficiency. A decrease in this metric minimizes the probability of a cash gap, which is critically important for Cardio Diagnostics (CDIO) as it scales PrecisionCHD tests and expands insurance coverage in the US.